Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2026Annals of MedicineOpen Access

Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJunjing YinSYShuyuan YuHWHongying Wu

Discussion

Loading...

Member takes

Overview

Single-arm clinical trial evaluates the XVRd regimen's safety and efficacy in high-risk multiple myeloma, suggesting promising outcomes.

Key Points

  • Evaluate the efficacy and safety of the XVRd regimen in newly diagnosed multiple myeloma patients with high-risk features.
  • Single-arm, open-label, prospective observational study
  • Recruited 30 patients between August 2022 and November 2024, aged ≥18 years
  • Induction phase followed by maintenance therapy, with a focus on overall response rate and minimal residual disease.
  • Overall response rate was 93.3% (28/30), with 5 achieving stringent complete response
  • Median progression-free survival was 16.2 months (95% CI, 14.6-NA), with a 1-year PFS rate of 89%
  • Safety profile was manageable, indicating tolerability of the XVRd regimen.

Cite This Study

Yin et al. (2026) studied this question.

synapsesocial.com/papers/6a72e802226790f370657773https://doi.org/10.1080/07853890.2026.2703403
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with extramedullary disease: a multicenter study2024
  2. 2Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  3. 3Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.2026 · 2 citations
  4. 4Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study2024 · 14 citations
  5. 5Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series2024 · 1 citations